Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony diagnoz raka jajnika (różne typy)
- •Co najmniej jeden widoczny guz do zmierzenia (min. 10 mm na CT/MRI lub 20 mm na zdjęciu klatki piersiowej)
- •Wiek minimum 18 lat
- •Co najmniej jedno poprzednie leczenie platynąkiem z powodu raka jajnika
- •Rak powrócił lub się rozprzestrzenia po platynaku lub wrócił w ciągu 6 miesięcy
- •Co najmniej 3 tygodnie po ostatniej chemioterapii
- •Stan zdrowotny oceniony na 0-2 w skali ECOG
- •Oczekiwana długość życia minimum 3 miesiące
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 10, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Stanford University
Palo Alto, United States
Trial contact
Bela Shah
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.